Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Pharma Reports Earnings Doubled in Q1

publication date: Apr 26, 2011
Just before the company completes its $1.8 billion Hong Kong IPO, Shanghai Pharmaceuticals Holding reported its Q1 net income more than doubled, rising 107% to 849 million RMB ($130 million). The big earnings jump came on a comparatively modest 27% increase in sales, which hit 11.9 billion RMB ($1.8 billion). The company is definitely on a roll: earnings were up 90% in 2010 over the year earlier. No particular mystery about this. To make itself more attractive to investors, Shanghai Pharma has been in a restructuring frenzy during the last two years. More details....

Stock Symbol: (SHA: 601607)     Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital